Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

EdiGene Forms University Collaboration for RNA Edited Genetic Therapies

publication date: Nov 17, 2021

EdiGene, a China gene editing company, announced a research collaboration with the University of Wisconsin–Madison to identify candidates for genetic disease therapies. EdiGene’s US R&D Center will work with the David Gamm Laboratory at UWM to evaluate the pharmacological properties of RNA base editing candidates derived from EdiGene's LEAPER™ RNA platform. The program will focus on in vivo therapies for ophthalmology indications. In September, EdiGene started a China Phase I trial of its gene-editing hematopoietic stem cell therapy to treat transfusion dependent β-thalassemia, a rare genetic disease. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital